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Background: Liver transplantation is the only life-extending intervention for primary
sclerosing cholangitis (PSC). Given the co-existence with colitis, patients may also
require colectomy; a factor potentially conferring improved post-transplant out-
comes.
Aim: To determine the impact of restorative surgery via ileal pouch-anal anastomo-
sis (IPAA) vs retaining an end ileostomy on liver-related outcomes post-transplanta-
tion.
Methods: Graft survival was evaluated across a prospectively accrued transplant
database, stratified according to colectomy status and type.
Results: Between 1990 and 2016, 240 individuals with PSC/colitis underwent
transplantation (cumulative 1870 patient-years until first graft loss or last follow-up
date), of whom 75 also required colectomy. A heightened incidence of graft loss
was observed for the IPAA group vs those retaining an end ileostomy (2.8 vs 0.4
per 100 patient-years, log-rank P = 0.005), whereas rates between IPAA vs no
colectomy groups were not significantly different (2.8 vs 1.7, P = 0.1). In addition,
the ileostomy group experienced significantly lower graft loss rates vs. patients
retaining an intact colon (P = 0.044). The risks conferred by IPAA persisted when
taking into account timing of colectomy as related to liver transplantation via time-
dependent Cox regression analysis. Hepatic artery thrombosis and biliary strictures
were the principal aetiologies of graft loss overall. Incidence rates for both were not
significantly different between IPAA and no colectomy groups (P = 0.092 and
P = 0.358); however, end ileostomy appeared protective (P = 0.007 and 0.031,
respectively).
Conclusion: In PSC, liver transplantation, colectomy + IPAA is associated with simi-
lar incidence rates of hepatic artery thrombosis, recurrent biliary strictures and re-
transplantation compared with no colectomy. Colectomy + end ileostomy confers
more favourable graft outcomes.
The Handling Editor for this article was Professor Stephen Harrison, and it was accepted
for publication after full peer-review.
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1 | INTRODUCTION
Primary sclerosing cholangitis (PSC) is a chronic, progressive
cholangiopathy for which therapy other than liver transplantation is
ineffective.1 While PSC is considered to be a rare disease,2 it is one
associated with significant and disproportionate unmet need,
wherein ~50% of patients reach a clinical endpoint of death or liver
transplantation.3,4 Indeed, PSC accounts for >10% of all United
Kingdom liver transplant activity, while also being the lead indication
for transplantation in Nordic countries.5,6 Although transplantation is
a proven life-extending intervention, the incidence of graft loss is
significantly greater compared with that observed for non-PSC
aetiologies.7
The vast majority of patients with PSC also develop inflamma-
tory bowel disease (IBD) at some point, predominantly colitis phe-
notypically.3,8 While the clinical course of gut and liver disease do
not necessarily parallel, a series of epidemiological findings indicate
that co-existence of colitis is associated with poorer transplant-free
survival when compared with PSC patients without an IBD his-
tory.3,9 Moreover, rates of progression to liver transplantation or
death may be lower for patients treated with colectomy prior to
PSC diagnosis.10
Following liver transplantation, colectomy does not appear pro-
tective against graft loss per se,11 although data from several centres
indicate that retention of an intact colon, particularly one associated
with ongoing inflammatory activity post-transplant, increases the risk
of developing post-transplant complications including disease recur-
rence and hepatic artery thrombosis.7,12-16
The definitive, first-line surgical treatment for patients with
ulcerative colitis (UC) refractory to medical therapy is a subtotal
colectomy.17 This can either be performed leaving an end ileostomy
in situ, or followed by ileorectal anastomosis (IRA), or restorative
proctocolectomy and ileal pouch-anal anastomosis (IPAA). In
patients with UC alone, health-related global quality of life is similar
for ‘well-informed’ individuals choosing to retain an ileostomy vs
those with a pelvic pouch,18,19 the latter being opted for in approx-
imately 30% of cases.20 This rate has remained relatively constant
over the last decade and outcomes are generally good for patients
without PSC.
In a Nationwide study from Sweden, the pouch failure rates fol-
lowing restorative proctocolectomy were not significantly different
between patients with UC alone vs PSC/UC,21 although other inves-
tigators have reported consistently poorer nocturnal pouch function
and worse quality of life scores in the latter group, in addition to
high rates of recurrent pouchitis, pouch mucosal atrophy and dys-
plastic change.22-24 With respect to the post-liver transplant setting,
58%-62% of patients may develop exacerbating features of acute
pouchitis.25-27 IRA may also not be favoured given the increased risk
of rectal cancer associated with PSC specifically.28,29
While the frequency of pouch-related complications is well docu-
mented in the PSC literature, the impact of IPAA on graft survival
following liver transplantation is ill defined. To this effect, we
determined the post-transplant clinical course in PSC patients with
an IPAA, specifically compared with those who elected to retain an
end ileostomy following their colonic resection, or individuals with
colitis yet no colectomy. Our aim was to improve the post-transplant
survival estimates for patients and further understand the recipient
risk factors contributing to graft loss.
2 | PATIENTS AND METHODS
2.1 | Study population
We reviewed a prospectively collected, well-characterised database
of all adult patients undergoing liver transplantation at the Univer-
sity Hospitals Birmingham NHS Foundation Trust from 1990 up to
January 2016. The hospital transplant database is maintained
prospectively, details of which can be found elsewhere.30 The
immunosuppression protocol for liver transplant recipients across
our study period is provided in Table S1. In order to ensure
robustness, accuracy and completeness of data, the transplant
database was cross-referenced with an independently accrued reg-
istry of all patients having previously attended or under current
follow-up of our dedicated PSC clinic. Our intent-to-study popula-
tion comprised all patients undergoing liver transplantation with
PSC and colitis.
Details pertaining to IBD and colectomy status (including type
IPAA or ileostomy) were collected retrospectively for individuals hav-
ing undergone colonic resection prior to transplantation, and
prospectively in those requiring bowel surgery at any point in the
post-transplant course. All those with an intact colon underwent at
least one colonoscopy following liver transplantation. Surveillance
colonoscopy continued for patients with known colitis, until the
point of colectomy or death, in keeping with recommended intervals
during the era of clinical follow-up.31,32
2.2 | Clinical endpoints
The “time-dependent” primary clinical endpoint for our study was
the incidence rate of first graft loss (death censored). Given the
starting point and prolonged observation period of our study, aeti-
ologies of graft loss were classified broadly, according to hepatic
artery thrombosis, recurrent biliary stricturing disease in the absence
of hepatic artery occlusion, graft rejection, and primary graft non-
function. Secondary endpoints included the incidence rate of recipi-
ent mortality, or graft loss/mortality as a combined outcome
measure. Patients were censored at the date of last follow-up if they
did not meet the clinical endpoint in question.
2.3 | Statistical analysis
Data are presented using the median and interquartile range (IQR)
for continuous variables. The nonparametric Mann-Whitney U test
was used to determine whether significant differences existed
TRIVEDI ET AL. | 323
between 2 groups or the Kruskal-Wallis test with Bonferroni-Dunn
post hoc correction with >2 groups. Differences in nominal data
were compared by Fisher’s exact test. A P value of <0.05 was
deemed statistically significant. Risk stratification as pertains to clini-
cal outcomes’ analysis was performed through Kaplan-Meier sur-
vivorship estimates, and significant differences between groups were
assessed by Log-rank/Mantel-Cox testing. The proportion of clinical
events is presented as incidence rates (IR) per 100-patient-years (pt-
yrs) with respective confidence intervals (95% CI). Time zero was set
at the point of first liver transplantation. Given that colorectal resec-
tion may be performed after liver transplantation in PSC, the impact
of colectomy “type” (IPAA or retaining an end ileostomy) was also
determined as a time-dependent covariate via Cox regression analy-
sis.33 All data were analysed using IBM SPSS v.23.0 (Armonk, NY:
IBM Corp.).
2.4 | Quality control and ethical approval
Completeness, plausibility and validity of the data were indepen-
dently verified (by PJT, JR and ES), including personalised objective
review of all historical medical charts. Local regulatory board
approval was obtained prior to study initiation and database/chart
review (CAB-04186-12 and CARMS-02246).
3 | RESULTS
3.1 | Characteristics of the patient population
Over a 26-year observation period, 240 patients with PSC and colitis
underwent liver transplantation and comprised our intended study
population (175 patients were men; median age of the overall cohort
at time of transplant of 47 years [IQR 37-57 years]). Across this
cohort, we observed 27 incidents of graft loss and 88 recipient
deaths over time, yielding a cumulative follow-up until re-transplan-
tation or mortality of 1870 patient-years and 2043 patient-years,
respectively (Figure 1).
3.2 | Colectomy does not protect against liver graft
loss or recipient mortality
Overall, 31% of patients with PSC and colitis underwent colectomy
(n = 75/240), either prior to or following first liver transplantation
and before reaching the primary clinical endpoint. Observing the
study cohort in its entirety, the incidence of graft loss or patient
mortality was no different between the colectomy vs no colectomy
groups (Figure 2), even on restricting analysis to those undergoing
colonic resection prior to liver transplantation (Figure S1).
We observed no significant prognostic impact with regard to
graft loss conferred by male sex, recipient age at time of transplant
or at time of colectomy, pre-transplant MELD score, era in which
transplantation was performed, biliary anastomosis type, split liver
donation, or organ donation after circulatory death (P value >0.05
for all tested covariates).
3.3 | The incidence of graft loss is increased for
patients with IPAA
Within the colectomy group, 28% (21/75 patients) subsequently
underwent creation of an IPAA, akin to the rate reported for UC
patients overall.20 Formation of IPAA was more common when colo-
nic resection took place prior to liver transplantation (n = 14/21 vs
20/54 patients who retained end an ileostomy, P = 0.024) and when
surgery was performed at a younger age (39 vs 49 years, P = 0.001;
Table 1). Overall, 76 patients from our entire cohort (32%) devel-
oped at least one episode of acute rejection, with no significant dif-
ference between our three study groups (Chi-square P = 0.710).
All 21 patients with an IPAA reported deterioration in symptoms
related to pouch function, subjectively, within 12 months of liver
transplantation. Of 21 patients, 15 patients displayed endoscopically
and histologically confirmed inflammation during this time; and all
episodes were acute by definition,34 albeit recurrent at a frequency
<3 times per year.
Although colectomy overall was not protective, we observed
significant differences in the incidence of graft loss between the
IPAA patient group (IR: 2.8 [95% CI: 2.0-4.5]; 1-, 5-, and 10-year
graft loss rates: 85%, 79% and 70%), those without colectomy (IR:
1.7 [1.5-2.1], 91%, 88% and 88%) and the ileostomy group (IR:
0.4 [0.3-0.5], 1-, 5-, and 10-year graft loss rates: 100%, 98% and
95%) (overall log-rank P value between the 3 groups = 0.038;
Figure 3), findings which persisted in subanalysis only of patients
undergoing colonic resection prior to liver transplantation (Fig-
ure S2).
In a direct pairwise comparison, it became apparent that statisti-
cally significant differences were attributable to improved liver graft
survival experienced by the end ileostomy group vs patients with an
IPAA and compared with the no colectomy group (log-rank P
value = 0.005 and 0.044, respectively) (Figure 3). By contrast, the
incidence of graft loss was similar between the IPAA group and
those without colectomy (P = 0.1).
However, when evaluating the impact of colectomy type as a
time-dependent covariate in Cox regression analysis, individuals with
an IPAA carried greater risk of graft loss vs both the ileostomy (time
adjusted HR: 7.32, 95% CI 1.42-37.83, P = 0.017) and no colectomy
groups (time adjusted hazard ratio [HR]: 3.15, 95% CI 1.17-8.50,
P = 0.023).
Between our colectomy groups more specifically, IPAA was more
often fashioned when the indication for colonic resection was active
colitis (Table 1). Nevertheless, the negative impact of IPAA on graft
survival was retained in a subanalysis within the latter cohort specifi-
cally (Figure 4).
3.4 | The incidence of post-transplant
complications is attenuated in patients retaining an
ileostomy, but not an IPAA
Hepatic artery thrombosis (44%) and recurrent biliary stricturing dis-
ease (37%) comprised the principal aetiologies of graft loss in our
324 | TRIVEDI ET AL.
overall cohort, with lesser contributions from primary graft nonfunc-
tion and acute graft rejection (15% and 4%, respectively).
As such, 25 individual patients developed hepatic artery throm-
bosis (10%); and independently, 75 patients developed recurrent bil-
iary strictures (31%), contributing to 12 and 10 incidents of 1st graft
loss, respectively. The event rate of hepatic artery thrombosis was
elevated in the IPAA group by greater than fourfold that of the
ileostomy group (IR: 2.8 [95% CI: 2.0-4.6] vs 0.6 [95% CI 0.5-0.7]
per-100-pt-yrs, respectively; log-rank P = 0.007); but not signifi-
cantly different compared with the patient cohort retaining an intact
colon (IR: 1.5 [1.3-1.8] per-100-pt-yrs; P = 0.092). No differences
were found in the proportion of donors with hepatic artery anomaly
across the 3 groups, although 6 recipients did require formation of
an aortic conduit (IPAA, n = 1; no colectomy group, n = 5). A list of
the anatomical variants and arterial reconstruction types performed
is provided in Tables S2 and S3.
Our institution and others have previously reported a lower inci-
dence of recurrent biliary stricturing disease post-transplant for
patients undergoing colectomy.12-14,16 In the present cohort, we
found that this potentially protective effect was confined to patients
retaining an end ileostomy (Figure 5A), whereas the incidence of
recurrent biliary strictures was not significantly different between
IPAA and no colectomy groups (Figure 5B). Episodes of acute rejec-
tion did not significantly impact the development of recurrent biliary
disease (HR: 1.605, 95% CI: 0.647-1.752, P = 0.804), neither posed
a risk factor for graft loss overall (HR: 0.913, 95% CI: 0.409-2.036,
P = 0.823).
No significant differences were seen across our 3 groups in
terms of patient mortality or graft loss/mortality as a combined end-
point (Figure 6).
4 | DISCUSSION
In Europe and North America, the burden of PSC on liver transplant
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F IGURE 1 Clinical outcomes following liver transplantation for primary sclerosing cholangitis. Kaplan-Meier estimates illustrating the
incidence of (A) graft loss, (B) patient mortality, and (C) graft loss/patient morality as a combined endpoint in our overall PSC/colitis cohort
undergoing liver transplantation. Incidence rates are presented per 100-patient-years and the respective 95% confidence intervals. Event-free
survival rates are calculated using the life-tables method. Time zero is set from the point of liver transplantation. PSC, primary sclerosing
cholangitis; Pt. yrs., patient years; Pts. at risk, patients at risk
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therapy. A societal impact is also evident given the high frequency
with which graft loss occurs relative to other aetiologies.15,35 As clin-
icians we strive to provide the best donor organ possible to our
patients, as well as identify putative risk factors for loss that sit with
the recipient. An interesting observation is the fact that persistence
of colitis after transplantation may increase the risk of biliary disease
recurrence,12-14,16 although this does not always translate to changes
in graft survival. Indeed, many individuals still experience graft loss
in the absence of recurrent PSC and despite undergoing colec-
tomy.11
To further understand the clinical course that patient’s experi-
ence, and to offer better counselling specifically to those needing
colonic resection, we examined the impact of colectomy type across
a large PSC/UC transplant cohort. In so doing, we identify IPAA as a
significant risk factor for graft loss, even for patients undergoing
colectomy prior to transplantation or when the impact of colectomy
type was determined in time-dependent covariate analysis.
Conversely, graft survival was maximised in the colectomy group
retaining an end ileostomy.
The main aetiologies necessitating re-transplantation in our
studied cohort were hepatic artery thrombosis or recurrent biliary
disease. As discussed, the presence of an intact colon has been
put forward as a risk factor for the latter,12-14,16 albeit inconsis-
tently validated.11,36,37 Herein, we identify that any protective
effect conferred following colectomy (with regard to recurrent bil-
iary disease) is skewed towards the patient group retaining an end
ileostomy, whereas no benefit is evident for patients with an
IPAA. As patients with PSC and IPAA often develop pouchitis and
poorer pouch function,23 it is plausible that persistent or recurrent
episodes of intestinal inflammation also contribute to an elevated
risk of thrombotic injury, akin to that when the colon is
retained.7,12-14,16,38 Although speculative, evidence to support this
hypothesis includes the fact that our ileostomy group experienced
the lowest incidence of hepatic artery thrombosis; in addition to
findings that show persistent subclinical intestinal inflammation in
PSC associated colitis,39,40 associations between pouchitis and
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F IGURE 2 Post-liver transplant clinical course according to colectomy status. Kaplan-Meier estimates stratified according to colectomy
status for all transplanted PSC patients with colitis, specifically for graft loss only (A), mortality only (B) and graft loss/mortality as a combined
clinical endpoint (C). Incidence rates are presented per 100-patient-years and the respective 95% confidence intervals. Event-free survival rates
are calculated using the life-tables method. Time zero is set from the point of liver transplantation. PSC, primary sclerosing cholangitis; Pt. yrs,
patient years; Pts. at risk, patients at risk
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While speculative, our data argue against the fact that an aggres-
sive ‘liver phenotype’ post-transplant is driven purely by predisposi-
tion towards aggressive IBD. This is because colectomy overall, a
marker of colitis activity in its own right, was in itself not a risk
factor for re-transplantation. Instead, the negative impact on graft
outcome was associated with either (1) retaining an intact colon
post-transplant, and by proxy, persistence of ulcerative colitis as a
comorbidity, or (2) formation of IPAA in the event colectomy was
performed. Detailing the pathogenic mechanisms of PSC and pouchi-
tis are beyond the scope of the current study, but of interest, muco-
sal dysbiosis has been called into question in both conditions.43
Whether unique commensal disturbances correlate with risk of allo-
graft recurrence, thromboembolic events or actual graft loss is also
an area of ongoing investigation.44 Given the increased incidence of
hepatic artery thrombosis in patients with PSC and IBD,7,38 which
we now confirm is relevant to those with IPAA, a dedicated evalua-
tion of thrombotic tendency is needed in this at-risk population.45
An early study from the Mayo clinic indicated a 10-year graft
loss rate of 12.5% for transplanted PSC patients with an IPAA.46
The Cleveland Clinic have also published their experience; and in a
total cohort of 79 transplanted PSC patients, they also found an
increased frequency of hepatic artery thrombosis (27% in the IPAA
group vs 18% in the no colectomy group) although surprisingly none
went onto be re-transplanted, and a comparative outcomes’ analysis
against a control ileostomy group was not presented.27 By contrast,
ours is also the first study to robustly determine the impact of colec-
tomy status and type in a time-dependent outcomes’ analysis for
patients with PSC/UC and show improved graft survival when
patients elect to retain an ileostomy.
In selected studies, acute rejection has also been linked to devel-
opment of recurrent biliary disease post-transplantation,15 and it is
conceivable that alloreactive immune responses may recruit long-
lived memory T cells from the gut implicated with the development
of PSC prior to transplantation. Alternatively, abrupt changes in
immunosuppression while treating rejection may trigger immune
reconstitution and subsequent reactivity to biliary epithelial antigenic
epitopes associated with the development of recurrent disease.
However, links between acute rejection and recurrent disease are
inconsistently validated; and despite poorer outcomes in our IPAA
group, acute rejection occurred at a similar frequency to those
TABLE 1 Characteristics of PSC/UC patients undergoing liver transplantation
IPAA (n = 21) End ileostomy (n = 54)
UC but no colectomy
(n = 165)
Male sex 19 (90%) 44 (81%) 112 (68%)
Recipient age at time of liver transplantation, years 41 (34-55) 49 (42-56) 47 (35-59)
MELD score pre-transplantationa 17 (12-27) 16 (11-21) 13 (10-19)
Era of transplantation
1990-2000 8 (38%) 20 (37%) 50 (30%)
2000-2010 8 (38%) 21 (39%) 51 (31%)
2010-2016 5 (24%) 13 (24%) 64 (39%)
Organ donation after circulatory death 0 (0%) 2 (4%) 20 (12%)
Living-related organ donation 0 (0%) 0 (0%) 2 (1%)
Split liver donation 1 (5%) 3 (6%) 18 (11%)
Duct-to-duct biliary anastomosis 3 (14%) 8 (15%) 17 (10%)
Episode of acute rejection 5 (24%) 18 (33%) 53 (32%)
Greater than 1 episode of acute rejection 1 2 9
Age at time of colectomy, years 39 (33-43) 49 (39-58)
Era of colectomy
1990-2000 11 (52%) 15 (28%)
2000-2010 6 (29% 22 (41%)
2010-2016 4 (19%) 17 (31%)
Colectomy post liver transplantation 7 (33%) 33 (61%)
Colectomy indication
Active colitis 20 (95%) 35 (65%)
Dysplasia/neoplasia 1 (5%) 12 (22%)
Combination 0 (0%) 4 (7%)
Other 0 (0%) 3 (6%)
IPAA, ileal pouch-anal anastomosis; MELD, model for end-stage liver disease score; UC, ulcerative colitis.
aMELD scores not captured for procedures performed prior to January 1994 (n = 36/240; n = 2, 6 and 28 patients in the IPAA, end ileostomy and no
colectomy groups, respectively).
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having an ileostomy or without colectomy. Moreover, no causal rela-
tionship was identified between acute rejection and development of
either recurrent biliary disease or graft loss overall.
The therapeutic arena of IBD continues to evolve, and with
regard to PSC/colitis specifically, a wealth of attention has focussed
in targeting the integrin a4b7.47,48 Although this strategy may not
impact liver biochemistry,47 the potential role in attenuating disease
progression is of particular interest given that recruitment of a4b7+
mucosal lymphocytes are implicated in the pathogenesis of PSC liver
disease,49 including recurrence post-transplantation for patients with
colitis and an intact colon.15
While a single-centre report, the Birmingham liver unit con-
tributes 25% of all liver transplant activity in the United Kingdom.5
Our transplant database is maintained prospectively, but we never-
theless lack historical data such as quantifiable IBD severity scores,
extent of colonic involvement and pharmacological treatment regi-
mens; neither have we accrued details on IPAA function and quality
of life indices, or severity of liver disease at the time colectomy was
undertaken. This is because the tertiary referral nature of our trans-
plant unit means that for many patients, IBD care delivery was
undertaken at a different centre. An additional restriction is the fact
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F IGURE 3 Liver graft loss rates following transplantation according to colectomy type. Kaplan-Meier survival estimates of liver graft loss
stratified by colectomy type for all transplanted PSC patients with colitis. Incidence rates are presented per 100-patient-years and the
respective 95% confidence intervals. Event-free survival rates are calculated using the life-tables method. Time zero is set from the point of
liver transplantation. Results of the overall log-rank test are presented in the graphic. Outcome of testing in a pairwise Log-rank test is as
follows: IPAA vs the ileostomy group; P = 0.005; no colectomy vs. the ileostomy group; P value = 0.044; and IPAA vs no colectomy group,
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stratified by colectomy type. Incidence
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and the respective 95% confidence
intervals. Event-free survival rates are
calculated using the life-tables method.
Time zero is set from the point of liver
transplantation. IPAA, ileal pouch-anal
anastomosis; PSC, primary sclerosing
cholangitis; Pt. yrs., patient years; Pts. at
risk, patients at risk
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precluding multivariable analysis of robust statistical power. Unlike
reports from other centres,21 our cohort was also devoid of an IRA
group. This is because in PSC/UC, IRA is associated with a >6-fold
risk of developing rectal cancer compared with IRA in UC alone,28
leading to avoidance in fear of malignant degeneration. A further
limitation is that our prospectively captured data records did not
include incidence or severity of ischaemia-reperfusion injury (IRI)
specifically, a factor which may have reduced graft viability for cer-
tain individuals. Nevertheless, when IRI leads to early graft loss, this
is as a result of primary graft nonfunction. The latter occurred in a
total of 4 patients across our entire study cohort, all within the no
colectomy group (vs no patient with an IPAA or ileostomy).
Moreover, the greatest risk of IRI is in the context of organ donation
using marginal grafts, mainly livers donated after circulatory death
(DCD), whereas all patients within our IPAA group were recipients
of organ donation after brain death.
We must also be mindful that our prolonged study period par-
allels the evolving indications for liver transplantation. For
instance, the Model for End-Stage Liver Disease (MELD) score
was only developed in the year 200050,51 and not captured for
the few within our cohort transplanted prior to January 1994. A
similar caution applies to the progressive knowledge that sur-
rounds transplant-related complications. Consequently, we evalu-
ated the incidence of all recurrent/non-anastomotic biliary
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F IGURE 5 Incidence of recurrent biliary strictures post-transplant. The incidence of recurrent biliary strictures that developed in the
absence of hepatic artery occlusion is shown for the overall cohort, stratified by colectomy type. Event rates are depicted for the no
colectomy vs ileostomy group in (A) and no colectomy vs the IPAA group in (B). Incidence rates presented per 100-patient-years and the
respective 95% confidence intervals. Event-free survival rates are calculated using the life-tables method. Time zero is set from the point of
liver transplantation. *5/54 patients in the ileostomy group underwent their colectomy following development of a recurrent biliary stricture,
and thus re-assigned to the “no colectomy” group for this analysis. IPAA, ileal pouch-anal anastomosis; PSC, primary sclerosing cholangitis; Pt.
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Graft loss or mortality
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F IGURE 6 Combined patient and graft survival rates. Kaplan-Meier survival estimates of patient mortality (A) and patient mortality/graft
loss as a combined endpoint (B) stratified by colectomy type for all transplanted PSC patients with colitis. Incidence rates are presented per
100-patient-years and the respective 95% confidence intervals. Event-free survival rates are calculated using the life-tables method. Time zero
is set from the point of liver transplantation. IPAA, ileal pouch-anal anastomosis; PSC, primary sclerosing cholangitis; Pt. yrs., patient years; Pts.
at risk, patients at risk
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strictures collectively, for attributing more specific labels to lesions
that developed in the early 1990s (for instance, differentiating
ischaemic-type biliary lesions from recurrent PSC) may neither be
correct nor consistent with contemporary definitions and imaging
modalities.7,13 In any event, the lack of protocol cholangiographic/
angiographic surveillance is caveat across most outcome studies in
transplantation including our own, and it is conceivable that the
subclinical incidence of vascular events and biliary complications is
higher than actually reported.
The decision to undergo pouch formation is largely a surgical
consideration led by patient choice.52 However, given an era of
organ shortage in liver transplantation, we advocate that all with
PSC who require colorectal resection be counselled about potential
risks of poorer pouch function compared with UC alone,23 and also
the relatively increased incidence of graft loss, although we cannot
be certain of a definite causal relationship between existing pouch
and liver transplant failure at this stage. In light of our study find-
ings, the impact of IPAA, pouch function and pouchitis on clinical
events as relate to the native liver in PSC also requires investiga-
tion, and represents an area of ongoing research activity. Further
prospective and independent validation is of the utmost importance
in these areas and ideally should proceed via multi-centre collabora-
tive networks and across a globally representative patient popula-
tion.3
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